|Bid||0.00 x 1100|
|Ask||0.00 x 800|
|Day's Range||55.06 - 55.40|
|52 Week Range||36.26 - 56.34|
|Beta (3Y Monthly)||1.51|
|PE Ratio (TTM)||68.26|
|Earnings Date||Oct 31, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||58.64|
The Syneos Health® Insights Hub, a dynamic destination for what’s next thinking and future-focused insights, today released 2020 Health Trends: Changing Lives and Life Sciences. Compiled from hundreds of global trend watchers working on the frontlines of healthcare, the report provides tangible ways for biopharmaceutical companies to navigate what’s ahead to realize the full potential of innovation. “As we enter the next decade, the state of biopharmaceutical change continues to accelerate – from scientific advances redefining what’s possible to new technologies that are changing how we generate and act on data to improve health,” said Alistair Macdonald, Chief Executive Officer, Syneos Health.
The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.
Medical technology companies are rising bullishly in 2019. The best-performing medical stocks tend to have high Composite Ratings, reflecting strong growth metrics vs. all other stocks.
MORRISVILLE, N.C. and NEW YORK , Nov. 21, 2019 -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today released “Real World.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
MORRISVILLE, N.C., Nov. 13, 2019 -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research.
MORRISVILLE, N.C., Nov. 12, 2019 -- Syneos Health® (Nasdaq:SYNH), a leading biopharmaceutical solutions organization combining a Contract Research Organization (CRO) and a.
MORRISVILLE, N.C. and NEW YORK, Nov. 12, 2019 -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, and AiCure, an AI and.
Syneos Health (SYNH) delivered earnings and revenue surprises of 4.82% and -0.44%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Highlights GAAP revenue of $1,177.0 million for the three months ended September 30, 2019, representing growth of 5.6% compared to the same period in 2018.Adjusted revenue.
NEW YORK, NY / ACCESSWIRE / October 31, 2019 / Syneos Health, Inc. (NASDAQ: SYNH ) will be discussing their earnings results in their 2019 Third Quarter Earnings to be held on October 31, 2019 at 8:00 ...
Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Boston Scientific (BSX) is making an all-out effort to solidify its core businesses and invest in the new technologies as well as the global markets. This reflects on the sales uptick in Q3.